Senior Management’s Further Increase in EuroEyes Shareholdings Demonstrates Strong Confidence in the Group’s Prospect

22nd July 2022

Senior Management’s Further Increase in EuroEyes Shareholdings Demonstrates Strong Confidence in the Group’s Prospect

Senior management and key members of the Board of Directors at EuroEyes International Eye Clinic Limited (“EuroEyes” or the “Company”, together with its subsidiaries, the “Group”, HKEX: 1846), a leading global vision correction service provider, have acquired a total of 1,089,000 shares (0.32% of total shares issued) since the start of the year of 2022, indicating their strong confidence in the long-term prospect of the Group.

The senior management and key board members and number of shares they have each acquired during the period were:

  • Dr. Jørn Slot Jørgensen, Chairman and Executive Director: 624,000 shares (0.19% of total shares issued)
  • Mr. Jannik Jonas Slot Jørgensen, Executive Director: 60,000 shares (0.02% of total shares issued)
  • Dr. Markus Braun, Executive Director: 25,000 shares (0.01% of total shares issued)
  • Dr. Ralf-Christian Lerche, Executive Director: 30,000 shares (0.01% of total shares issued)
  • Mr. Marcus Huascar Bracklo, Non-executive Director: 350,000 shares (0.11% of total shares issued)

 

In a recent announcement, EuroEyes stated it has resumed operations in all clinics in China after the suspension of business across major cities where strict COVID-19 control measures were imposed. Besides, the Group expects the global economic downturn to have no significant adverse impact on its business, and will take a prudent approach to its expansion plan, strives to improve its profitability, and maintains a healthy cash flow, which builds resilience under an uncertain economic environment.

EuroEyes has a far-reaching geographical coverage with operations in Germany, China, Denmark and United Kingdom, which helps diversify potential business risks from a single market, supporting the sustainable growth of the Group.